METHODS:
l The design is a retrospective claims data analysis.
• The data source is the database of the Institute for Applied Health Research (InGef) Berlin, formerly HRI Health Risk Institute, which includes approximately 6.7 million insured anonymities who originate from 63 statutory health insurances in Germany. The observation period was from 2012 to 2016 and analyses were performed by the InGef institute. A sample with approximately 4 million insured persons was drawn and stratified by age and gender according to the official demographic structure of the German statutory health insured population (DeStatis, Dec 31st, 2013).
• The target population consists of patients who met following criteria with regard to the observation period from 2012 to 2016:
1. Main diagnosis of AS (using relevant ICD-10 codes according to Table 1) , and/or 2. Treatment with approved biological agent for AS at least for three months
• If the diagnosis occurred before 2012 patients were only selected if they were already on treatment at the beginning of the observation period in 2012.
• The relevant patient sample was then split into three groups with regard to the observation period from 2012 to 2016:
1. Patients who start a biological treatment ("New")
2. Patients who get continuous treatment with the same biological ("Repeater")
3. Patients who switch biological ("Switcher")
• In sum, 1743 patients could be included in the sample.
• The study evaluated direct medical costs (drugs, outpatient care and hospital admission), hospital admission and change in medication.
• Treatment costs included costs for biological agents which were approved for the treatment of AS (as of April 2017, see also Table 2 ). Furthermore, the following medication groups were considered to be AS related (see also • In case that a patient changed therapy during the observation period, he was further included only if he continued receiving a biological agent.
• Figure 1 depicts an overview of the analysis of the sample. 
RESULTS:
l Most patients with AS are aged above 18, thereby the proportion below 17 years' account for less than 1%. The average age of all age cohorts is 44.7 years with no difference by gender (44.7 yr men vs. 44.8 yr women). The proportion of men is higher than of women (63.6% male vs 36.4% female) (see also Figure 2 ). 
Notes:
* The costs could be slightly overestimated due to potential intersections of patients who begin, repeat or switch the therapy. ** With regard to 2016, comprehensive data sets only exist for Q1/2016 and Q2/2016, data from Q3/2016 is incomplete. This has to be taken into account when interpreting the data.
CONCLUSIONS:
l Adalimumab and etanercept are those biological agents who are mainly used for treating AS.
• The total treatment costs grew steadily over the last four years. Hereby, the key cost driver were the biological agents.
• The total costs in 2015 were € 22.5 million and on average € 16'793 per patient. Sex distribu>on of total popula>on (in %)
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